Coherus BioSciences Company Profile (NASDAQ:CHRS)

About Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences logoCoherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CHRS
  • CUSIP: N/A
  • Web: www.coherus.com
Capitalization:
  • Market Cap: $569.95 million
  • Outstanding Shares: 51,346,000
Average Prices:
  • 50 Day Moving Avg: $13.06
  • 200 Day Moving Avg: $18.81
  • 52 Week Range: $10.80 - $31.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.11
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $165.24 million
  • Price / Sales: 4.21
  • Book Value: $0.63 per share
  • Price / Book: 21.51
Profitability:
  • EBIDTA: ($111,050,000.00)
  • Net Margins: -73.89%
  • Return on Equity: -307.41%
  • Return on Assets: -63.38%
Debt:
  • Debt-to-Equity Ratio: 3.27%
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
Misc:
  • Average Volume: 791,767 shs.
  • Beta: 4.33
  • Short Ratio: 10.44
 

Frequently Asked Questions for Coherus BioSciences (NASDAQ:CHRS)

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Monday, August, 7th. The company reported ($1.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.29) by $0.21. The firm had revenue of $1.40 million for the quarter. Coherus BioSciences had a negative return on equity of 307.41% and a negative net margin of 73.89%. View Coherus BioSciences' Earnings History.

When will Coherus BioSciences make its next earnings announcement?

Coherus BioSciences is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Coherus BioSciences.

Where is Coherus BioSciences' stock going? Where will Coherus BioSciences' stock price be in 2017?

9 equities research analysts have issued 1 year price targets for Coherus BioSciences' stock. Their forecasts range from $24.00 to $46.00. On average, they anticipate Coherus BioSciences' share price to reach $37.00 in the next twelve months. View Analyst Ratings for Coherus BioSciences.

What are analysts saying about Coherus BioSciences stock?

Here are some recent quotes from research analysts about Coherus BioSciences stock:

  • 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (8/15/2017)
  • 2. Maxim Group analysts commented, "Coherus announced that the company received a CRL (Complete Response Letter) regarding its BLA for CHS-1701 (Neulasta)." (6/12/2017)
  • 3. Credit Suisse Group analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities. Positives from the 4Q16 release that support our thesis: 1) In November of ’16, ACRS reported that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions. In February 2017, ACRS submitted a New Drug Application NDA for A-101 40% Topical Solution for the treatment of SK to the FDA. 2) During ’16 ACRS also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts. 3) ACRS recently completed a Phase 1 clinical trial of ATI-50001, its investigational JAK inhibitor, for the treatment of alopecia totalis and alopecia universalis. And, 4) ACRS had cash and cash equivalents of $174.1MM as of 12/31/16." (3/16/2017)

Who are some of Coherus BioSciences' key competitors?

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the folowing people:

  • Dennis M. Lanfear, Chairman of the Board, President, Chief Executive Officer
  • Jean-Frederic Viret Ph.D., Chief Financial Officer
  • Peter K. Watler, Chief Technology Officer
  • Alan C. Herman Ph.D., Chief Scientific Officer
  • Barbara K. Finck M.D., Chief Medical Officer
  • Mats Wahlstrom, Lead Independent Director
  • Christos Richards, Director
  • August J. Troendle M.D., Director
  • James I. Healy M.D. Ph.D., Independent Director
  • V. Bryan Lawlis Jr. Ph.D., Independent Director

Who owns Coherus BioSciences stock?

Coherus BioSciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (4.40%), State Street Corp (2.76%), UBS Asset Management Americas Inc. (2.71%), TIAA CREF Investment Management LLC (1.95%) and Northern Trust Corp (0.90%). Company insiders that own Coherus BioSciences stock include Alan C Herman, Christos Richards, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Institutional Ownership Trends for Coherus BioSciences.

Who sold Coherus BioSciences stock? Who is selling Coherus BioSciences stock?

Coherus BioSciences' stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Teachers Advisors LLC, Candriam Luxembourg S.C.A., Columbus Circle Investors, Kennedy Capital Management Inc., Pacad Investment Ltd., TD Asset Management Inc. and ProShare Advisors LLC. Company insiders that have sold Coherus BioSciences stock in the last year include Alan C Herman, Dennis M Lanfear, Jean-Frederic Viret and Mats Wahlstrom. View Insider Buying and Selling for Coherus BioSciences.

Who bought Coherus BioSciences stock? Who is buying Coherus BioSciences stock?

Coherus BioSciences' stock was bought by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., TIAA CREF Investment Management LLC, State of Wisconsin Investment Board, State Street Corp, Macquarie Group Ltd., Northern Trust Corp, Lazard Asset Management LLC and C WorldWide Group Holding A S. View Insider Buying and Selling for Coherus BioSciences.

How do I buy Coherus BioSciences stock?

Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Coherus BioSciences' stock price today?

One share of Coherus BioSciences stock can currently be purchased for approximately $13.55.


MarketBeat Community Rating for Coherus BioSciences (NASDAQ CHRS)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Coherus BioSciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Coherus BioSciences (NASDAQ:CHRS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.00 (173.06% upside)

Analysts' Ratings History for Coherus BioSciences (NASDAQ:CHRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017J P Morgan Chase & CoReiterated RatingOverweight -> Overweight$32.00 -> $25.00LowView Rating Details
6/14/2017Credit Suisse GroupReiterated RatingOutperform$38.00 -> $24.00LowView Rating Details
6/13/2017Citigroup Inc.Lower Price TargetBuy$38.00 -> $33.00MediumView Rating Details
6/13/2017Cowen and CompanyReiterated RatingOutperform$45.00HighView Rating Details
6/13/2017BMO Capital MarketsLower Price TargetOutperform$54.00 -> $43.00HighView Rating Details
6/13/2017Robert W. BairdLower Price TargetOutperform$40.00 -> $37.00HighView Rating Details
6/12/2017Maxim GroupLower Price TargetBuy -> Buy$44.00 -> $40.00MediumView Rating Details
5/21/2017Barclays PLCReiterated RatingOverweight$46.00HighView Rating Details
11/25/2016Standpoint ResearchInitiated CoverageBuy$40.00N/AView Rating Details
(Data available from 8/22/2015 forward)

Earnings

Earnings History for Coherus BioSciences (NASDAQ:CHRS)
Earnings by Quarter for Coherus BioSciences (NASDAQ:CHRS)
Earnings History by Quarter for Coherus BioSciences (NASDAQ CHRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017N/AView Earnings Details
8/7/2017Q2 2017($1.29)($1.08)$1.40 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.54)($1.54)$0.16 millionViewListenView Earnings Details
3/13/2017Q4 2016($1.11)($1.71)$10.00 million$0.84 millionViewListenView Earnings Details
11/9/2016Q3 2016($1.56)$1.67$7.20 million$162.80 millionViewListenView Earnings Details
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)$12.36 millionViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)$8.63 million$10.20 millionViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 million$6.87 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 million$5.81 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)
Current Year EPS Consensus Estimate: $-4.16 EPS
Next Year EPS Consensus Estimate: $-2.65 EPS

Dividends

Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Coherus BioSciences (NASDAQ:CHRS)
Insider Ownership Percentage: 32.88%
Institutional Ownership Percentage: 72.41%
Insider Trades by Quarter for Coherus BioSciences (NASDAQ:CHRS)
Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)
Insider Trades by Quarter for Coherus BioSciences (NASDAQ:CHRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017Alan C HermanInsiderSell17,535$15.02$263,375.70View SEC Filing  
7/5/2017Alan C HermanInsiderSell600$15.00$9,000.00View SEC Filing  
4/3/2017Alan C HermanInsiderSell11,333$20.73$234,933.09View SEC Filing  
1/25/2017Jean-Frederic ViretCFOSell3,900$27.00$105,300.00View SEC Filing  
12/16/2016Jean-Frederic ViretCFOSell3,900$28.30$110,370.00View SEC Filing  
12/8/2016Mats WahlstromDirectorSell53,583$27.52$1,474,604.16View SEC Filing  
12/1/2016Alan C HermanInsiderSell11,333$27.40$310,524.20View SEC Filing  
10/21/2016Jean-Frederic ViretCFOSell3,900$30.62$119,418.00View SEC Filing  
10/3/2016Alan C HermanInsiderSell11,333$25.69$291,144.77View SEC Filing  
9/26/2016Jean-Frederic ViretCFOSell3,900$29.88$116,532.00View SEC Filing  
9/21/2016Dennis M LanfearInsiderSell4,060$31.75$128,905.00View SEC Filing  
9/16/2016Dennis M LanfearInsiderSell2,900$31.79$92,191.00View SEC Filing  
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.83View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.82View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.00View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Coherus BioSciences (NASDAQ:CHRS)
Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)
Source:
DateHeadline
streetinsider.com logoCoherus BioSciences (CHRS) to Raise Up to $150M in from Temasek in Two Tranches
www.streetinsider.com - August 21 at 5:02 PM
finance.yahoo.com logoCoherus Secures Private Placement from Temasek
finance.yahoo.com - August 21 at 5:02 PM
finance.yahoo.com logoCoherus Bio Jumps on Private Placement
finance.yahoo.com - August 21 at 5:02 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (CHRS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - August 15 at 9:52 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (CHRS) Insider Alan C. Herman Sells 17,535 Shares
www.americanbankingnews.com - August 10 at 8:02 PM
fool.com logoHere's Why Coherus Biosciences Rose as Much as 22.2% Today - Motley Fool
www.fool.com - August 10 at 3:25 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Coherus BioSciences Inc.
finance.yahoo.com - August 9 at 10:22 PM
finance.yahoo.com logoEdited Transcript of CHRS earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 10:22 PM
finance.yahoo.com logoHere's Why Coherus Biosciences Rose as Much as 22.2% Today
finance.yahoo.com - August 8 at 4:56 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (CHRS) Releases Quarterly Earnings Results, Beats Estimates By $0.21 EPS
www.americanbankingnews.com - August 8 at 12:28 PM
globenewswire.com logoCoherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results - GlobeNewswire (press release)
globenewswire.com - August 7 at 10:47 PM
streetinsider.com logoCoherus BioSciences (CHRS) Files Petition for IPR of Amgen's ... - StreetInsider.com
www.streetinsider.com - August 7 at 10:47 PM
finance.yahoo.com logoCoherus BioSciences Files Petition for Inter Partes Review of ENBREL® Patent 8,163,522
finance.yahoo.com - August 7 at 5:37 PM
finance.yahoo.com logoCoherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results
finance.yahoo.com - August 7 at 5:37 PM
finance.yahoo.com logoCoherus BioSciences reports 2Q loss
finance.yahoo.com - August 7 at 5:37 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (NASDAQ:CHRS) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - August 5 at 11:18 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 29 at 12:52 PM
reuters.com logoAbbVie to remain cautious on drug pricing, shares fall - Reuters
www.reuters.com - July 28 at 6:49 PM
globenewswire.com logoCoherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th - GlobeNewswire (press release)
globenewswire.com - July 24 at 4:47 PM
nasdaq.com logoCoherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th - Nasdaq
www.nasdaq.com - July 24 at 11:38 AM
finance.yahoo.com logoCoherus BioSciences to Report Second Quarter 2017 Financial Results on August 7th
finance.yahoo.com - July 24 at 11:38 AM
americanbankingnews.com logoCoherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 4 at 1:08 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (NASDAQ:CHRS) Expected to Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - July 3 at 2:28 PM
streetinsider.com logoCoherus BioSciences (CHRS) Reduces Workforce by 51 Employees - StreetInsider.com
www.streetinsider.com - June 28 at 2:34 AM
streetinsider.com logoCoherus BioSciences (CHRS) Reduces Workforce by 51 Employees
www.streetinsider.com - June 27 at 9:32 PM
streetinsider.com logoCoherus BioSciences (CHRS) Reports Alternative Fill-Finish Vendor
www.streetinsider.com - June 27 at 4:31 PM
streetinsider.com logoCoherus BioSciences (CHRS) Reports Alternative Fill-Finish Vendor - StreetInsider.com
www.streetinsider.com - June 26 at 5:00 PM
finance.yahoo.com logoCoherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
finance.yahoo.com - June 21 at 3:13 AM
americanbankingnews.com logoCoherus BioSciences, Inc. (CHRS) Earns Outperform Rating from Credit Suisse Group
www.americanbankingnews.com - June 14 at 5:20 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (CHRS) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - June 13 at 4:04 PM
nasdaq.com logoCoherus Biosciences Inc. (CHRS) Is Sinking After FDA Complete Response Letter
www.nasdaq.com - June 13 at 3:51 PM
rttnews.com logoCoherus Biosciences Inc. (CHRS) Sank To An 11-Month Low On FDA News
www.rttnews.com - June 13 at 3:51 PM
finance.yahoo.com logoETFs with exposure to Coherus BioSciences, Inc. : June 12, 2017
finance.yahoo.com - June 13 at 3:51 PM
thestreet.com logoBiotech Movers: Acceleron, Clovis, Coherus - TheStreet.com
www.thestreet.com - June 13 at 3:51 PM
americanbankingnews.com logoCoherus BioSciences' (CHRS) "Buy" Rating Reiterated at J P Morgan Chase & Co
www.americanbankingnews.com - June 13 at 2:44 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (CHRS) Given a $38.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - June 13 at 2:44 PM
americanbankingnews.com logoCoherus BioSciences, Inc. (CHRS) Stock Rating Reaffirmed by Citigroup Inc.
www.americanbankingnews.com - June 13 at 12:52 PM
nasdaq.com logoMid-Afternoon Market Update: Coherus Biosciences Drops After FDA Response Letter; TrovaGene Shares Surge - Nasdaq
www.nasdaq.com - June 13 at 12:41 PM
247wallst.com logoWhy Coherus Biosciences Shares Are Crashing - 24/7 Wall St.
247wallst.com - June 13 at 12:41 PM
finance.yahoo.com logoCoherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : June 13, 2017
finance.yahoo.com - June 13 at 12:41 PM
finance.yahoo.com logoCoherus Stock Plummets as FDA Rejects Neulasta Biosimilar
finance.yahoo.com - June 13 at 12:41 PM
finance.yahoo.com logoCoherus Biosciences Inc (CHRS) Hits ‘Speed Bump’ for CHS-1701; Maxim Remains Positive
finance.yahoo.com - June 13 at 12:41 PM
americanbankingnews.com logoCoherus BioSciences' (CHRS) "Outperform" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - June 13 at 10:58 AM
americanbankingnews.com logoCoherus BioSciences' (CHRS) "Outperform" Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - June 13 at 10:58 AM
americanbankingnews.com logoBMO Capital Markets Reaffirms "Outperform" Rating for Coherus BioSciences, Inc. (CHRS)
www.americanbankingnews.com - June 13 at 10:58 AM
benzinga.com logoMid-Afternoon Market Update: Coherus Biosciences Drops After FDA Response Letter; TrovaGene Shares Surge - Benzinga
www.benzinga.com - June 12 at 5:18 PM
finance.yahoo.com logoWhy Pandora Media, Coherus Biosciences, and Erin Energy Slumped Today
finance.yahoo.com - June 12 at 5:18 PM
americanbankingnews.com logoCoherus BioSciences' (CHRS) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - June 12 at 4:20 PM
finance.yahoo.com logoCoherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 4:54 PM
americanbankingnews.com logoCoherus Biosciences Inc (CHRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 9 at 2:38 PM

Social

Chart

Coherus BioSciences (CHRS) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by MarketBeat.com Staff